SEVs derived from fibroblast-like mesenchymal cells have been engineered to carry short interfering RNA (siRNA) or short hairpin RNA (shRNA) to specifically target oncogenic KrasG12D, resulting in enhanced targeting of oncogenic KRAS, with enhanced suppression and significantly increased overall survival (OS) in mouse models of pancreatic cancer [201]. This evidence concerns the gene KRAS and pancreatic neoplasm.